Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates
Company continues Development of Two Investigational Therapeutic Candidates
Merck, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/Covid-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.

Symbolic image
pixabay.com
“We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We are resolute in our commitment to contribute to the global effort to relieve the burden of this pandemic on patients, health care systems and communities.”
Due to the discontinuation, the company will record a charge in the fourth quarter of 2020. The charge will be included in Merck’s generally accepted accounting principles (GAAP) results, but will not impact non-GAAP results.
Merck and its collaborators plan to submit the results of the Phase 1 studies for V590 and V591 for publication in a peer-reviewed journal. In addition to advancing the development and production of MK-7110 and MK-4482, Merck will continue to conduct SARS-CoV-2/COVID-19 research. Merck will also continue to evaluate the potential of the measles-virus vector and vesicular stomatitis virus vector-based platforms and pursue broader pandemic-response capabilities. The COVID-19 pandemic underscores the need for our company and our industry to continue to invest in research to address threats to health security.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Half a needle in a haystack - New method rapidly detects trace amounts of small molecule compounds

New sensors can detect single protein molecules - Modified carbon nanotubes could be used to track protein production by individual cells.
Gladstone scientists reprogram skin cells into brain cells - Innovative technique lays groundwork for novel stem cell therapies
Co.don AG is awarded the US-Patent: Process to produce cell transplants patented successfully
Integrated DNA Technologies expands global sales network - Company now selling directly to customers in South Korea
Fluidigm-Singapore completes final milestone toward full manufacturing operations - Off-shore fab positions Fluidigm to move rapidly into the real-time qPCR market
Eppendorf grows faster than the market
Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
ZEISS: High-Tech Drives Growth - Medical technology and industrial metrology business still on track for growth

Innophore GmbH - Graz, Austria
OctoPlus appoints Jan Hendrik Egberts as CEO
